Introduction A comprehensive Nitrosamine Risk Assessment for Peptide APIs examines the specific chemical pathways through which reactive secondary and tertiary […]
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a
Introduction: Nitrosamine Risk Assessment for Combination Oral Solid Dosage Forms is particularly important when a pharmaceutical product contains two or
Introduction Nitrosamine Leachables Testing is a comprehensive analytical and regulatory process used to evaluate pharmaceutical packaging and drug delivery systems
Nitrosamine Leachables Testing: From Risk Assessment to Confirmatory LC-MS/MS Analysis Read More »
Introduction Nitrosamine Testing for Antidepressants and SSRIs is a specialized analytical and regulatory process designed to detect, quantify, and control
Introduction Nitrosamine Testing for Antibiotics and Beta-Lactam APIs is a specialized analytical mandate focused on the detection, identification, and quantification
Introduction Nitrosamine Risk in Drug-Drug Combination Products has emerged as a significant toxicological challenge because combining multiple active pharmaceutical ingredients
Introduction Nitrosamines from Excipients primarily arise when trace levels of nitrite impurities present in inactive formulation components react with susceptible
Introduction Nitrosamine Control Strategy Development Services offer a comprehensive, science-driven framework for identifying, quantifying, and controlling mutagenic N-nitroso impurities throughout
Introduction: Implementation of Nitrosamine Testing for Injectable Drug Products is a critical safety and regulatory requirement because parenteral drug products
